Advances in the clinical value of tissue inhibitors of metalloproteinase-2 and insulin-like growth factor binding protein 7 in sepsis associated-acute kidney injury
10.3760/cma.j.cn121430-20210624-00123
- VernacularTitle:金属蛋白酶组织抑制剂-2联合胰岛素样生长因子结合蛋白7对脓毒症相关性急性肾损伤的临床应用价值研究进展
- Author:
Wei JIANG
1
;
Ruiqiang ZHENG
Author Information
1. 扬州大学临床医学院，江苏省苏北人民医院重症医学科，江苏扬州 225001
- Keywords:
Tissue inhibitors of metalloproteinase-2;
Insulin-like growth factor-binding protein 7;
Cell cycle inhibitor protein blocker;
Acute kidney injury;
Sepsis
- From:
Chinese Critical Care Medicine
2022;34(1):105-109
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis is an important cause of acute kidney injury (AKI). About 60% of sepsis patients will develop AKI. At present, the standard of clinical diagnosis of AKI is still based on the changes in serum creatinine and urine volume. Because of its lag in time, it may lead to delay in treatment and increase the mortality. To find a new biomarker similar to "troponin" for the diagnosis of AKI, and to achieve the early diagnosis and prevention of AKI, is of great significance to reduce the mortality of AKI. In recent years, it has been found that tissue inhibitors of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) can be used for early diagnosis of sepsis associated-acute kidney injury (SA-AKI). They also have important values in risk stratification, prognosis judgment, intervention and other aspects of SA-AKI. In this paper, the research progress of the application of TIMP-2 and IGFBP7 in SA-AKI is reviewed.
